对比三阴和HER-2阳性乳腺癌新辅助化疗中病理完全缓解率的荟萃分析

A Contrastive Meta-analysis of Pathological Complete Response Rate in Neoadjuvant Chemotherapy between Triple-negative Breast Cancer and HER-2 Positive Breast Cancer

目的 对比三阴乳腺癌（TNBC）和人表皮生长因子受体2（HER-2）阳性乳腺癌在新辅助化疗（NAC）中获得的病理完全缓解（pCR）率,为循证医学提供更为确切的数据.方法 检索PubMed和Cochrane Collaboration Library数据库,纳入乳腺癌NAC中包含TNBC和HER-2阳性病例的文献,应用相对危险度（RR）对比TNBC和HER-2阳性两组患者获得的pCR率.结果 共纳入11篇文献,病例数量为1076,其中TNBC组获得28.2%的pCR率,HER-2阳性组为20.0%,两组RR为1.62,95%置信区间（confidence interval,CI）：1.30-2.03,无明显异质性和发表偏倚.结论 TNBC较HER-2阳性乳腺癌在NAC中获得更高pCR率.

Objective To compare the pathological complete response （pCR） rates in neoadjuvant chemothera- py （NAC） between triple-negative breast cancer （TNBC） and human epidermal growth factor receptor 2 （HER-2） posi- tive breast cancer so as to provide accurate data for evidence-based medicine. Methods Literature of NAC in treatment of TNBC and HER-2 positive breast cancer was retrieved from the PubMed and Cochrane Collaboration Library databases, and the pCR rate in patients with TNBC and HER-2 positive breast cancer was compared by using relative risk （RR）. Results There were 11 literature reviews of 1076 patients, and the pCR rate was 28.2% in TNBC group, and that in HER-2 positive group was 20.0%. The summary RR for pCR rate of the two groups was 1.62, and 95% confidence in- terval （CI） was 1.30-2.03. No obvious heterogeneity or publication bias was detected. Conclusion The pCR rate of TNBC in NAC is higher than that of HER-2 positive breast cancer.